Bloomberg News

Lilly, Amylin’s Byetta Approved for New Use by U.S. Regulators

October 19, 2011

Oct. 19 (Bloomberg) -- Eli Lilly & Co. and Amylin Pharmaceutical Inc.’s Byetta diabetes drug was approved by the U.S. Food and Drug Administration for a new use -- as an add-on treatment to insulin glargine for some type 2 diabetics.

Link to Statement:{NSN LTC2XC3TCF0G <GO>}

To contact the editor responsible for this story: Vivek Shankar at

The Aging of Abercrombie & Fitch
blog comments powered by Disqus